Supernus Pharmaceuticals annual shares outstanding
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Shares Outstanding History (SUPN)
Supernus Pharmaceuticals reported 57.5M shares outstanding at the end of fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 57.5M | 1.7M | +3.08% |
| 2024 | 2024-12-31 | 55.7M | 1.0M | +1.86% |
| 2023 | 2023-12-31 | 54.7M | 469,560 | +0.87% |
| 2022 | 2022-12-31 | 54.3M | 997,702 | +1.87% |
| 2021 | 2021-12-31 | 53.3M | 387,612 | +0.73% |
| 2020 | 2020-12-31 | 52.9M | 335,134 | +0.64% |
| 2019 | 2019-12-31 | 52.5M | 216,765 | +0.41% |
| 2018 | 2018-12-31 | 52.3M | 1.0M | +1.95% |
| 2017 | 2017-12-31 | 51.3M | 1.3M | +2.69% |
| 2016 | 2016-12-31 | 50.0M | 966,593 | +1.97% |
| 2015 | 2015-12-31 | 49.0M | 6.0M | +14.03% |
| 2014 | 2014-12-31 | 43.0M | 3.0M | +7.48% |
| 2013 | 2013-12-31 | 40.0M | 9.4M | +30.57% |
| 2012 | 2012-12-31 | 30.6M | 29.0M | +1742.12% |
| 2011 | 2011-12-31 | 1.7M | — | — |
Supernus Pharmaceuticals quarterly shares outstanding
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 58.2M | 2.0M | +3.64% |
| Q1 2026 | 2026-03-31 | 58.0M | 2.1M | +3.66% |
| Q4 2025 | 2025-12-31 | 57.5M | 1.7M | +3.08% |
| Q3 2025 | 2025-09-30 | 57.1M | 1.9M | +3.44% |
| Q2 2025 | 2025-06-30 | 56.1M | 1.1M | +1.95% |
| Q1 2025 | 2025-03-31 | 56.0M | 1.3M | +2.31% |
| Q4 2024 | 2024-12-31 | 55.7M | 1.0M | +1.86% |
| Q3 2024 | 2024-09-30 | 55.2M | 965,477 | +1.78% |
| Q2 2024 | 2024-06-30 | 55.0M | 792,253 | +1.46% |
| Q1 2024 | 2024-03-31 | 54.7M | 469,560 | +0.87% |
| Q4 2023 | 2023-12-31 | 54.7M | 469,560 | +0.87% |
| Q3 2023 | 2023-09-30 | 54.3M | 997,702 | +1.87% |
| Q2 2023 | 2023-06-30 | 54.3M | 997,702 | +1.87% |
| Q1 2023 | 2023-03-31 | 54.3M | 997,702 | +1.87% |
| Q4 2022 | 2022-12-31 | 54.3M | 997,702 | +1.87% |
| Q3 2022 | 2022-09-30 | 53.3M | 387,612 | +0.73% |
| Q2 2022 | 2022-06-30 | 53.3M | 387,612 | +0.73% |
| Q1 2022 | 2022-03-31 | 53.3M | 387,612 | +0.73% |
| Q4 2021 | 2021-12-31 | 53.3M | 387,612 | +0.73% |
| Q3 2021 | 2021-09-30 | 52.9M | 198,361 | +0.38% |
| Q2 2021 | 2021-06-30 | 52.9M | 244,398 | +0.46% |
| Q1 2021 | 2021-03-31 | 52.9M | 331,323 | +0.63% |
| Q4 2020 | 2020-12-31 | 52.9M | 335,134 | +0.64% |
| Q3 2020 | 2020-09-30 | 52.7M | 207,185 | +0.39% |
| Q2 2020 | 2020-06-30 | 52.6M | 175,048 | +0.33% |
| Q1 2020 | 2020-03-31 | 52.5M | 162,911 | +0.31% |
| Q4 2019 | 2019-12-31 | 52.5M | 216,765 | +0.41% |
| Q3 2019 | 2019-09-30 | 52.5M | 205,923 | +0.39% |
| Q2 2019 | 2019-06-30 | 52.4M | 269,702 | +0.52% |
| Q1 2019 | 2019-03-31 | 52.4M | 740,257 | +1.43% |
| Q4 2018 | 2018-12-31 | 52.3M | 1.0M | +1.95% |
| Q3 2018 | 2018-09-30 | 52.3M | 995,006 | +1.94% |
| Q2 2018 | 2018-06-30 | 52.2M | 1.4M | +2.85% |
| Q1 2018 | 2018-03-31 | 51.6M | 1.4M | +2.80% |
| Q4 2017 | 2017-12-31 | 51.3M | 1.3M | +2.69% |
| Q3 2017 | 2017-09-30 | 51.3M | 1.7M | +3.48% |
| Q2 2017 | 2017-06-30 | 50.7M | 1.2M | +2.47% |
| Q1 2017 | 2017-03-31 | 50.2M | 805,161 | +1.63% |
| Q4 2016 | 2016-12-31 | 50.0M | 966,593 | +1.97% |
| Q3 2016 | 2016-09-30 | 49.5M | 852,644 | +1.75% |
| Q2 2016 | 2016-06-30 | 49.5M | 1.1M | +2.20% |
| Q1 2016 | 2016-03-31 | 49.4M | 1.9M | +4.02% |
| Q4 2015 | 2015-12-31 | 49.0M | 6.0M | +14.03% |
| Q3 2015 | 2015-09-30 | 48.7M | 5.8M | +13.41% |
| Q2 2015 | 2015-06-30 | 48.4M | 6.3M | +14.96% |
| Q1 2015 | 2015-03-31 | 47.5M | 5.5M | +13.00% |
| Q4 2014 | 2014-12-31 | 43.0M | 3.0M | +7.48% |
| Q3 2014 | 2014-09-30 | 42.9M | — | — |
| Q2 2014 | 2014-06-30 | 42.1M | 11.2M | +36.20% |
| Q1 2014 | 2014-03-31 | 42.0M | 11.2M | +36.09% |
| Q4 2013 | 2013-12-31 | 40.0M | 9.4M | +30.57% |
| Q2 2013 | 2013-06-30 | 30.9M | 6.5M | +26.49% |
| Q1 2013 | 2013-03-31 | 30.9M | 29.2M | +1736.09% |
| Q4 2012 | 2012-12-31 | 30.6M | 29.0M | +1742.12% |
| Q3 2012 | 2012-09-30 | 24.5M | — | — |
| Q2 2012 | 2012-06-30 | 24.5M | — | — |
| Q1 2012 | 2012-03-31 | 1.7M | — | — |
| Q4 2011 | 2011-12-31 | 1.7M | — | — |
Supernus Pharmaceuticals shares outstanding trends
Over the last five fiscal years, Supernus Pharmaceuticals's shares outstanding moved from 52.9M to 57.5M, a change of 4.6M. The latest reported quarter, Q2 2026, shows 58.2M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
